More than a Decade of Experience and Still No Consensus: Controversies in Iron Therapy

[摘要] During the past decade, the integration of recombinant human erythropoietin (EPO) and maintenance intravenous iron therapy into standard anemia management protocols has significantly altered the treatment of anemia in patients who are on hemodialysis (HD). Hemoglobin levels have increased inexorably and now average almost 12 g/dl (1). The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines state that intravenous iron usually is required for the provision of optimal iron stores to maximize erythropoiesis-stimulating agent (ESA) efficiency in patients who are on dialysis (2). Intravenous iron therapy is needed in patients who are on HD because these patients experience ongoing blood (iron) losses, and oral iron fails to maintain adequate iron stores.

[学科分类] 泌尿医学

[关键词] Bone marrow necrosis;Sickle cell disease;Hyperhemolysis syndrome